No Data
The Pacific Securities: The Sector's profits improved significantly in Q1, and the pharmaceutical industry is expected to see a rapid increase in concentration.
The trend of increasing concentration in the pharmaceutical industry and the strong becoming stronger is expected to continue to strengthen.
Hong Kong Stock Announcement Treasure Hunt | STANCHART's first quarter profit attributable to the parent company's Shareholders is 1.59 billion US dollars, an increase of 13% year-on-year.
Kangnai Optical (02276) intends to invest in the construction of an automated resin lens production line through its wholly-owned subsidiary in Japan.
CSPC Pharmaceutical Gets US FDA Nod for Metabolism Disease Drug Trial
CSPC PHARMA (01093.HK): JMT202 (recombinant fully human anti-βKLOTHO monoclonal antibody) has received clinical trial approval in the USA.
On May 2, Gelonghui reported that CSPC PHARMA (01093.HK) announced that the restructured fully human anti-β Klotho monoclonal antibody drug JMT202 developed by the group has been approved by the USA Food and Drug Administration (FDA) to conduct clinical research in the USA. This product was also approved by the National Medical Products Administration of China in May 2024 and is currently undergoing clinical trials in China. This product acts as an FGFR1c/β Klotho receptor agonist, specifically activating the FGFR1c/β Klotho receptor complex by binding to the β Klotho protein.
Express News | CSPC Pharmaceutical - Jmt202 Obtains Clinical Trial Approval in U.S.
Express News | Ob Holdings - Letters of Intent Entered Into by Orient Biotech With Units of CSPC Pharmaceutical Group
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}